Published in N Engl J Med on November 13, 2011
An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome | NCT00809965
A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med (2013) 2.84
New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. Eur Heart J (2013) 2.81
2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. J Interv Card Electrophysiol (2012) 2.08
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. Eur Heart J (2013) 1.53
Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol (2013) 1.40
[Not Available]. Kardiol Pol (2012) 1.39
Recent advances in antithrombotic therapy after acute coronary syndrome. CMAJ (2013) 1.23
Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thromb J (2013) 1.15
Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions. Can Fam Physician (2014) 1.07
Approach to the new oral anticoagulants in family practice: part 1: comparing the options. Can Fam Physician (2014) 1.07
Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet (2014) 1.05
New anticoagulants: A concise review. J Trauma Acute Care Surg (2012) 1.04
Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. Heart Fail Rev (2014) 1.03
Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc (2014) 1.00
Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. Eur J Clin Pharmacol (2013) 0.98
Pharmacodynamics and pharmacokinetics during the transition from warfarin to rivaroxaban: a randomized study in healthy subjects. Br J Clin Pharmacol (2014) 0.95
Factor XI and contact activation as targets for antithrombotic therapy. J Thromb Haemost (2015) 0.94
Warfarin improved CT values of the coronary artery artherosclerotic plaque: evaluation by 64-MDCTA. BMJ Case Rep (2012) 0.93
Anticoagulation in heart failure: current status and future direction. Heart Fail Rev (2013) 0.93
Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol (2013) 0.93
Perspectives on the 2014 ESC/EACTS Guidelines on Myocardial Revascularization : Fifty Years of Revascularization: Where Are We and Where Are We Heading? J Cardiovasc Transl Res (2015) 0.92
Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012. Am Heart J (2014) 0.92
Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial. J Am Heart Assoc (2015) 0.92
Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis (2016) 0.91
Cardiovascular outcome studies with novel antidiabetes agents: scientific and operational considerations. Diabetes Care (2013) 0.89
Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison. Br J Clin Pharmacol (2014) 0.89
Stroke prevention in atrial fibrillation: understanding the new oral anticoagulants dabigatran, rivaroxaban, and apixaban. Thrombosis (2012) 0.87
Management of non-vitamin K antagonist oral anticoagulants in the perioperative setting. Biomed Res Int (2014) 0.87
Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials. BMJ Open (2012) 0.87
C-reactive protein and fibrin clot strength measured by thrombelastography after coronary stenting. Blood Coagul Fibrinolysis (2013) 0.87
Association between periprocedural bleeding and long-term outcomes following percutaneous coronary intervention in older patients. JACC Cardiovasc Interv (2012) 0.86
Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban. Clin Pharmacokinet (2014) 0.86
Relative Citation Ratio of Top Twenty Macedonian Biomedical Scientists in PubMed: A New Metric that Uses Citation Rates to Measure Influence at the Article Level. Open Access Maced J Med Sci (2016) 0.86
Edoxaban: an update on the new oral direct factor Xa inhibitor. Drugs (2014) 0.86
Atherosclerosis: Successes, Surprises, and Future Challenges. Circ Res (2016) 0.86
An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes. J Am Heart Assoc (2013) 0.86
Future prospects for contact factors as therapeutic targets. Hematology Am Soc Hematol Educ Program (2014) 0.85
Hot topics in cardiology: data from IABP-SHOCK II, TRILOGY-ACS, WOEST, ALTIDUDE, FAME II and more. Clin Res Cardiol (2012) 0.85
The role of prothrombin complex concentrates in reversal of target specific anticoagulants. Thromb J (2014) 0.85
Implementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review. Eur Heart J (2013) 0.84
New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag (2015) 0.84
Rivaroxaban and hemostasis in emergency care. Emerg Med Int (2014) 0.84
Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Eur Heart J (2016) 0.84
A new era in secondary prevention after acute coronary syndrome. N Engl J Med (2011) 0.84
Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence. Adv Hematol (2015) 0.84
Clinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indications. Drugs (2014) 0.83
Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes. Br J Clin Pharmacol (2012) 0.83
Clinical strategies for selecting oral anticoagulants in patients with atrial fibrillation. J Thromb Thrombolysis (2013) 0.83
RNAi targeting multiple cell adhesion molecules reduces immune cell recruitment and vascular inflammation after myocardial infarction. Sci Transl Med (2016) 0.82
Effect of co-administration of rivaroxaban and clopidogrel on bleeding time, pharmacodynamics and pharmacokinetics: a phase I study. Pharmaceuticals (Basel) (2012) 0.82
Stroke Prevention in Atrial Fibrillation: Where are We Now? Clin Med Insights Cardiol (2012) 0.82
Evaluation of clinical risk factors to predict high on-treatment platelet reactivity and outcome in patients with stable coronary artery disease (PREDICT-STABLE). PLoS One (2015) 0.82
Respiratory review of 2013: pulmonary thromboembolism. Tuberc Respir Dis (Seoul) (2013) 0.82
Factor XI Deficiency Protects Against Atherogenesis in Apolipoprotein E/Factor XI Double Knockout Mice. Arterioscler Thromb Vasc Biol (2016) 0.82
Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association. Circulation (2017) 0.82
Intracranial hemorrhage risk with the new oral anticoagulants: a systematic review and meta-analysis. J Neurol (2014) 0.82
Temporal trends in the occurrence and outcomes of atrial fibrillation in patients with acute myocardial infarction (from the Atherosclerosis Risk in Communities Surveillance Study). Am J Cardiol (2014) 0.82
What did we learn from new oral anticoagulant treatment? Thromb Res (2012) 0.81
Perioperative management of coagulation in nontraumatic intracerebral hemorrhage. Anesthesiology (2013) 0.81
Innate immune cells in ischaemic heart disease: does myocardial infarction beget myocardial infarction? Eur Heart J (2015) 0.81
Platelet function tests: why they fail to guide personalized antithrombotic medication. J Am Heart Assoc (2015) 0.81
Burden and Prevention of Adverse Cardiac Events in Patients with Concomitant Chronic Heart Failure and Coronary Artery Disease: A Literature Review. Cardiovasc Ther (2016) 0.80
Trials of novel oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation. Curr Cardiol Rev (2014) 0.80
Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar. Vasc Health Risk Manag (2014) 0.79
Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk. Vasc Health Risk Manag (2014) 0.79
Anticoagulant and antiplatelet therapy in patients with atrial fibrillation and coronary artery disease. Thrombosis (2012) 0.78
The new oral anticoagulants for the treatment of venous thromboembolism: a new paradigm shift in antithrombotic therapy. Curr Ther Res Clin Exp (2014) 0.78
Rivaroxaban, a factor Xa inhibitor, improves neovascularization in the ischemic hindlimb of streptozotocin-induced diabetic mice. Cardiovasc Diabetol (2015) 0.78
Measurement of rivaroxaban and apixaban in serum samples of patients. Eur J Clin Invest (2014) 0.78
Newer oral anticoagulant agents: a new era in medicine. Curr Cardiol Rev (2012) 0.78
Anticoagulant and Antiplatelet Prescribing Patterns for Patients with Atrial Fibrillation after Percutaneous Coronary Intervention. Can J Hosp Pharm (2016) 0.77
Review of the top 5 cardiology studies of 2011-12. Can Pharm J (Ott) (2013) 0.77
Lyso-Sulfatide Binds Factor Xa and Inhibits Thrombin Generation by the Prothrombinase Complex. PLoS One (2015) 0.77
Oral factor Xa inhibitors for the long-term management of ACS. Nat Rev Cardiol (2012) 0.77
Preventive strategies against bleeding due to nonvitamin K antagonist oral anticoagulants. Biomed Res Int (2014) 0.76
Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants. Clin Interv Aging (2015) 0.76
New targets for atherothrombosis. Arterioscler Thromb Vasc Biol (2014) 0.76
Nonvitamin K antagonist oral anticoagulants (NOACs): the tide continues to come in. Vasc Health Risk Manag (2015) 0.76
Effects of Rivaroxaban on Platelet Activation and Platelet-Coagulation Pathway Interaction: In Vitro and In Vivo Studies. J Cardiovasc Pharmacol Ther (2015) 0.76
Dual antiplatelet agents and Rivaroxaban for massive intracoronary thrombus in STEMI. Clin Case Rep (2015) 0.76
New oral anticoagulant agents after ACS. Eur Heart J Acute Cardiovasc Care (2012) 0.76
Evolving cardiovascular uses of direct-acting oral anticoagulants: a paradigm shift on the horizon? Intern Emerg Med (2017) 0.76
Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary artery stenting: hovering among bleeding risk, thromboembolic events, and stent thrombosis. Thromb J (2012) 0.75
Pharmacodynamic interplay of the P2Y(1), P2Y(12), and TxA(2) pathways in platelets: the potential of triple antiplatelet therapy with P2Y(1) receptor antagonism. Thromb Res (2012) 0.75
Anticoagulants for stroke prevention in nonvalvular atrial fibrillation: new agents and an updated understanding. Tex Heart Inst J (2012) 0.75
Representation of older adults in the late-breaking clinical trials American Heart Association 2011 Scientific Sessions. J Am Coll Cardiol (2012) 0.75
Targeting platelet thrombin receptor signaling to prevent thrombosis. Pharmaceuticals (Basel) (2013) 0.75
Antithrombotics for secondary prevention of noncardioembolic ischaemic stroke. Nat Rev Neurol (2012) 0.75
Antiplatelet and antithrombin strategies in acute coronary syndrome: state-of-the-art review. Curr Cardiol Rev (2012) 0.75
Potential role of rivaroxaban in patients with acute coronary syndrome. Drug Des Devel Ther (2012) 0.75
Challenging pulmonary embolism - A new generation of oral anticoagulants. J Thorac Dis (2012) 0.75
Optimal medical therapy for secondary prevention after an acute coronary syndrome: 18-month follow-up results at a tertiary teaching hospital in South Korea. Ther Clin Risk Manag (2016) 0.75
The need for multicentre cardiovascular clinical trials in Asia. Nat Rev Cardiol (2013) 0.75
Acute coronary syndromes in 2011: Walking the tightrope between efficacy and bleeding. Nat Rev Cardiol (2011) 0.75
The new oral anti-coagulants and the phase 3 clinical trials - a systematic review of the literature. Thromb J (2013) 0.75
[Rivarobaxan for patients with recent acute coronary syndrome : ATLAS ACS 2-TIMI 51]. Internist (Berl) (2013) 0.75
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Bariatric surgery: a systematic review and meta-analysis. JAMA (2004) 23.34
Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med (2004) 19.42
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25
Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2007) 17.85
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med (2015) 13.90
Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med (2012) 13.59
Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J (2008) 12.31
Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med (2011) 11.99
Universal definition of myocardial infarction. Circulation (2007) 11.69
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34
Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes. N Engl J Med (2014) 10.66
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med (2014) 10.54
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA (2004) 9.74
C-reactive protein levels and outcomes after statin therapy. N Engl J Med (2005) 9.47
Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med (2008) 9.25
Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med (2015) 8.69
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Third universal definition of myocardial infarction. Circulation (2012) 8.47
Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med (2012) 8.28
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA (2011) 8.24
Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98
Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med (2005) 7.80
Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70
Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med (2010) 7.39
Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia. Am J Hum Genet (2008) 7.33
A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA (2004) 7.32
Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med (2003) 7.25
Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA (2005) 6.81
Development and mapping of 2240 new SSR markers for rice (Oryza sativa L.). DNA Res (2002) 6.65
The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation (2006) 6.58
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J (2007) 6.51
Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation (2011) 6.36
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA (2010) 6.29
Possible Subclinical Leaflet Thrombosis in Bioprosthetic Aortic Valves. N Engl J Med (2015) 6.28
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med (2015) 6.12
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med (2010) 6.05
A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med (2009) 5.81
Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes. N Engl J Med (2015) 5.81
Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA (2006) 5.74
Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med (2007) 5.63
One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA (2007) 5.61
Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med (2006) 5.39
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med (2005) 5.28
Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med (2006) 5.24
Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery. N Engl J Med (2009) 5.19
Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA (2010) 5.10
Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ (2013) 5.08
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med (2006) 5.07
International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA (2006) 5.00
β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA (2012) 4.92
Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med (2009) 4.83
Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med (2011) 4.81
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med (2010) 4.73
Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet (2010) 4.72